Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 12, 2013, Pages 1871-1882

  Matsuda, Toshio ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Aggression; Anxiety; Depression; Isolation rearing; Osemozotan; Serotonin1A receptor

Indexed keywords

CORTICOSTERONE; LIGAND; METHAMPHETAMINE; OSEMOZOTAN; PSYCHOSTIMULANT AGENT; SEROTONIN 1A RECEPTOR;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DISEASE MODEL; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOALGESIA; ISOLATION PROCEDURE; MENTAL DISEASE; NEUROPHARMACOLOGY; NONHUMAN; PAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SENSITIZATION;

ANIMALS; DIOXANES; DIOXOLES; DOPAMINE; HUMANS; PREFRONTAL CORTEX; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84892582481     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00645     Document Type: Review

References (157)

1. De Vry J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl.), 121, 1-26 (1995).
2. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology, 38, 1083-1152 (1999).
3. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry, 53, 193-203 (2003).
4. Lucki I, Singh A, Kreiss DS. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci. Biobehav. Rev., 18, 85-95 (1994).
5. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res., 346, 205-230 (1985).
6. Vergé D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy S, Gozlan H, Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci., 6, 3474-3482 (1986).
7. Saudou F, Hen R. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem. Int., 25, 503-532 (1994).
8. Albert PR, Lembo P, Storring JM, Charest A, Saucier C. The 5-HT1A receptor: signaling, desensitization, and gene transcription. Neuropsychopharmacology, 14, 19-25 (1996).
9. Nicoll RA, Malenka RC, Kauer JA. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol. Rev., 70, 513-565 (1990).
10. Aghajanian GK. Electrophysiology of serotonin receptor subtypes and signal transduction pathways. Psychopharmacolgy: The Fourth Generation of Progress. (Bloom FR, Kupfer DJ eds.), Raven Press, New York, pp. 1451-1459 (1995).
11. Matsuda T, Yoshikawa T, Suzuki M, Asano S, Somboonthum P, Takuma K, Nakano Y, Morita T, Nakasu Y, Kim HS, Egawa M, Tobe A, Baba A. Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy)-1,3- benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors. Jpn. J. Pharmacol., 69, 357-366 (1995).
12. Abe M, Tabata R, Saito K, Matsuda T, Baba A, Egawa M. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)-amino]propoxy]-1,3- benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J. Pharmacol. Exp. Ther., 278, 898-905 (1996).
13. Einon DF, Morgan MJ. Early isolation produces enduring hyperactivity in the rat, but no effect upon spontaneous alternation. Q. J. Exp. Psychol., 30, 151-156 (1978).
14. Gentsch C, Lichtsteiner M, Feer H. Locomotor activity, defecation score and corticosterone levels during an open-field exposure: a comparison among individually and group-housed rats, and genetically selected rat lines. Physiol. Behav., 27, 183-186 (1981).
15. Gentsch C, Lichtsteiner M, Feer H. Behavioural comparisons between individually-and group-housed male rats: effects of novel environments and diurnal rhythm. Behav. Brain Res., 6, 93-100 (1982).
16. Wright IK, Ismail H, Upton N, Marsden CA. Effect of isolation rearing on 5-HT agonist-induced responses in the rat. Psychopharmacology (Berl.), 105, 259-263 (1991).
17. Heidbreder CA, Weiss IC, Domeney AM, Pryce C, Homberg J, Hedou G, Feldon J, Moran MC, Nelson P. Behavioral, neurochemical and endocrinological characterization of the early social isolation syndrome. Neuroscience, 100, 749-768 (2000).
18. Hall FS, Huang S, Fong GW, Pert A, Linnoila M. Effects of isolation-rearing on locomotion, anxiety and responses to ethanol in Fawn Hooded and Wistar rats. Psychopharmacology (Berl.), 139, 203-209 (1998).
19. Ago Y, Takahashi K, Nakamura S, Hashimoto H, Baba A, Ma tsuda T. Anxiety-like and exploratory behaviors of isolation-reared mice in the staircase test. J. Pharmacol. Sci., 104, 153-158 (2007).
20. Maisonnette S, Morato S, Brandao ML. Role of resocialization and of 5-HT1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test. Physiol. Behav., 54, 753-758 (1993).
21. Schreiber R, De Vry J. 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog. Neuropsychopharmacol. Biol. Psychiatry, 17, 87-104 (1993).
22. Hilakivi LA, Ota M, Lister RG. Effect of isolation on brain monoamines and the behavior of mice in tests of exploration, locomotion, anxiety and behavioral 'despair.' Pharmacol. Biochem. Behav., 33, 371-374 (1989).
23. Heritch AJ, Henderson K, Westfall TC. Effects of social isolation on brain catecholamines and forced swimming in rats: prevention by antidepressant treatment. J. Psychiatr. Res., 24, 251-258 (1990).
24. Potegal M, Einon D. Aggressive behaviors in adult rats deprived of playfighting experience as juveniles. Dev. Psychobiol., 22, 159-172 (1989).
25. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol. Psychiatry, 34, 361-372 (1993).
26. Wilkinson LS, Killcross SS, Humby T, Hall FS, Geyer MA, Robbins TW. Social isolation in the rat produces developmentally specific deficits in prepulse inhibition of the acoustic startle response without disrupting latent inhibition. Neuropsychopharmacology, 10, 61-72 (1994).
27. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biol. Psychiatry, 43, 436-445 (1998).
28. Coudereau JP, Monier C, Bourre JM, Frances H. Effect of isolation on pain threshold and on different effects of morphine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 21, 997-1018 (1997).
29. Tuboly G, Benedek G, Horvath G. Selective disturbance of pain sensitivity after social isolation. Physiol. Behav., 96, 18-22 (2009).
30. Meng Q, Li N, Han X, Shao F, Wang W. Peri-adolescence isolation rearing alters social behavior and nociception in rats. Neurosci. Lett., 480, 25-29 (2010).
31. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.), 156, 117-154 (2001).
32. Willner P. The validity of animal models of depression. Psychopharmacology (Berl.), 83, 1-16 (1984).
33. Ferrier IN. Treatment of major depression: is improvement enough? J. Clin. Psychiatry, 60 (Suppl. , 10-14 (1999).
34. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol. Psychiatry, 46, 1301-1308 (1999).
35. Barbui C, Hotopf M. Amitriptyline v. The rest: still the leading antidepressant after 40 years of randomized controlled trials. Br. J. Psychiatry, 178, 129-144 (2001).
36. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J. Clin. Psychopharmacol., 18, 89-91 (1998), letter.
37. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry, 60, 256-259 (1999).
38. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry, 158, 131-134 (2001).
39. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of ρ receptors in rat brain. Eur. J. Pharmacol., 307, 117-119 (1996).
40. Hayashi T, Su TP. ρ-1 Receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs, 18, 269-284 (2004).
41. Middlemiss DN, Fozard JR. 8-Hydroxy-2-(di-n-propylamino)tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur. J. Pharmacol., 90, 151-153 (1983).
42. Robinson DS, Rickels K, Feighner J, Fabre LF Jr, Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J. Clin. Psychopharmacol., 10 (Suppl.), 67S-76S (1990).
43. Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci. Biobehav. Rev., 32, 1087-1102 (2008).
44. Lacivita E, Di Pilato P, De Giorgio P, Colabufo NA, Berardi F, Perrone R, Leopoldo M. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opin. Ther. Pat., 22, 887-902 (2012).
45. Matsuda T, Kanda T, Seong YH, Baba A, Iwata H. p-Chlorophenylalanine attenuates the pituitary-adrenocortical response to 5-HT1A receptor agonists in mice. Eur. J. Pharmacol., 181, 295-297 (1990).
46. Bill DJ, Knight M, Forster EA, Fletcher A. Direct evidence for an important species difference in the mechanism of 8-OH-DPATinduced hypothermia. Br. J. Pharmacol., 103, 1857-1864 (1991).
47. Millan MJ, Rivet JM, Canton H, Le Marouille Girardon S, Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J. Pharmacol. Exp. Ther., 264, 1364-1376 (1993).
48. Hartley JE, Fletcher A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur. J. Pharmacol., 252, 329-332 (1994).
49. Jhanwar-Uniyal M, Moorjani B, Kahn AH. Indications of pre-and post-synaptic 5-HT1A receptor interactions in feeding behavior and neuroendocrine regulation. Brain Res., 646, 247-257 (1994).
50. Uphouse L, Caldarola Pastuszka M. Female sexual behaviour following intracerebral infusion of 5-HT1A agonist, 8-OH-DPAT, into the medal preoptic area. Brain Res., 601, 203-208 (1993).
51. Pomerantz SM, Hepner BC, Wertz JM. Serotonergic influences on male sexual behavior of rhesus monkeys: effects of serotonin agonists. Psychopharmacology (Berl.), 111, 47-54 (1993).
52. Uphouse L, Caldarola Pastuszka M, Montanez S. Intracerebral actions of the 5-HT1A agonists, 8-OH-DPAT and buspirone, and of the 5-HT1A partial agonist/antagonist, NAN-190, on female sexual behavior. Neuropharmacology, 31, 969-981 (1992).
53. Colpaert FC. 5-HT1A receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr. Opin. Investig. Drugs, 7, 40-47 (2006).
54. Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A. 5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Br. J. Pharmacol., 158, 232-242 (2009).
55. Asano S, Matsuda T, Yoshikawa T, Somboonthum P, Tasaki H, Abe M, Baba A. Interaction of orally administered 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino] propoxy}-1,3-benzodioxole (MKC-242) with 5-HT1A receptors in rat brain. Jpn. J. Pharmacol., 74, 69-75 (1997).
56. Hjorth S, Magnusson T. The 5-HT1A receptor agonist, 8-OHDPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn Schmiedebergs Arch. Pharmacol., 338, 463-471 (1988).
57. Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol., 96, 283-290 (1989).
58. Somboonthum P, Matsuda T, Asano S, Sakaue M, Baba A. MKC-242, a novel 5-HT1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OHDPAT in awake rats. Neuropharmacology, 36, 1733-1739 (1997).
59. Suzuki M, Matsuda T, Asano S, Somboonthum P, Takuma K, Baba A. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation. Br. J. Pharmacol., 115, 703-711 (1995).
60. Hajós-Korcsok E, McQuade R, Sharp T. Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (±)-MDL 73005EF and its enantiomers. Neuropharmacology, 38, 299-306 (1999).
61. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, Matsuda T. Postsynaptic 5-hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol., 129, 1028-1034 (2000).
62. Sakaue M, Ago Y, Sowa C, Koyama Y, Baba A, Matsuda T. The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze. Eur. J. Pharmacol., 458, 141-144 (2003).
63. Matsuda T, Somboonthum P, Suzuki M, Asano S, Baba A. Antidepressant-like effect by postsynaptic 5-HT1A receptor activation in mice. Eur. J. Pharmacol., 280, 235-238 (1995).
64. Abe M, Saito K. Reduction of wrap restraint stress-induced defecation by MKC-242, a novel benzodioxan derivative, via 5-HT1Areceptor agonist action in rats. Jpn. J. Pharmacol., 77, 211-217 (1998).
65. Sakaue M, Ago Y, Murakami C, Sowa C, Sakamoto Y, Koyama Y, Baba A, Matsuda T. Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT1A receptor activation in isolated mice. Eur. J. Pharmacol., 432, 163-166 (2001).
66. Matsuda T, Sakaue M, Ago Y, Sakamoto Y, Koyama Y, Baba A. Functional alteration of brain dopaminergic system in isolated aggressive mice. Jpn. J. Neuropsychopharmacol., 21, 71-76 (2001).
67. Sakaue M, Ago Y, Sowa C, Sakamoto Y, Nishihara B, Koyama Y, Baba A, Matsuda T. Modulation of 5-HT2A receptors of aggressive behavior in isolated mice. Jpn. J. Pharmacol., 89, 89-92 (2002).
68. Harasawa T, Ago Y, Itoh S, Baba A, Matsuda T. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marbleburying behavior in mice. Behav. Pharmacol., 17, 637-640 (2006).
69. Traber J, Glaser T. 5-HT1A receptor-related anxiolytics. Trends Pharmacol. Sci., 8, 432-437 (1987).
70. File SE, Gonzalez LE, Andrews N. Comparative study of pre-and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci., 16, 4810-4815 (1996).
71. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci., 15, 220-226 (1994).
72. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol., 15, 217-222 (1995).
73. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci., 19, 378-383 (1996).
74. Ago Y, Koyama Y, Baba A, Matsuda T. Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology, 45, 1050-1056 (2003).
75. Brenes JC, Rodríguez O, Fornaguera J. Differential effect of environment enrichment and social isolation on depressive-like behavior, spontaneous activity and serotonin and norepinephrine concentration in prefrontal cortex and ventral striatum. Pharmacol. Biochem. Behav., 89, 85-93 (2008).
76. Hall FS, Wilkinson LS, Humby T, Inglis W, Kendall DA, Marsden CA, Robbins TW. Isolation rearing in rats: pre-and postsynaptic changes in striatal dopaminergic system. Pharmacol. Biochem. Behav., 59, 859-872 (1998).
77. Jones GH, Hernandez TD, Kendall DA, Marsden CA, Robbins TW. Dopaminergic and serotonergic function following isolation rearing in rats. A study of behavioural responses and postmortem and in vivo neurochemistry. Pharmacol. Biochem. Behav., 43, 17-35 (1992).
78. Fulford AJ, Marsden CA. Effect of isolation-rearing on conditioned dopamine release in vivo in the nucleus accumbens of the rat. J. Neurochem., 70, 384-390 (1998).
79. Ago Y, Sakaue M, Baba A, Matsuda T. Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J. Neurochem., 83, 353-359 (2002).
80. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl.), 174, 45-53 (2004).
81. Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl.), 196, 293-301 (2008).
82. Yano K, Koda K, Ago Y, Kobayashi H, Kawasaki T, Takuma K, Matsuda T. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br. J. Pharmacol., 156, 173-180 (2009).
83. Ago Y, Koda K, Ota Y, Kita Y, Fukada A, Takuma K, Matsuda T. Donepezil, but not galantamine, blocks muscarinic receptormediated in vitro and in vivo responses. Synapse, 65, 1373-1377 (2011).
84. Koda K, Ago Y, Yano K, Nishimura M, Kobayashi H, Fukada A, Takuma K, Matsuda T. Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation. Br. J. Pharmacol., 162, 763-772 (2011).
85. Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T. Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl.), 225, 543-551 (2013).
86. Kawasaki T, Ago Y, Yano K, Araki R, Washida Y, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T. Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology, 60, 397-404 (2011).
87. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci., 48, 355-363 (1991).
88. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res., 708, 209-214 (1996).
89. Wȩdzony K, Maćkowiak M, Fijal K, Golembiowska K. Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur. J. Pharmacol., 305, 73-78 (1996).
90. Mason SL, Reynolds GP. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur. J. Pharmacol., 221, 397-398 (1992).
91. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPγS binding study. Eur. J. Pharmacol., 355, 245-256 (1998).
92. Sato M, Ago Y, Koda K, Nakamura S, Kawasaki T, Baba A, Matsuda T. Role of postsynaptic serotonin1A receptors in risperidoneinduced increase in acetylcholine release in rat prefrontal cortex. Eur. J. Pharmacol., 559, 155-160 (2007).
93. Sakaue M, Ago Y, Baba A, Matsuda T. The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficit of prepulse inhibition in mice. Psychopharmacology (Berl.), 170, 73-79 (2003).
94. Olivier B, Mos J, van del Heyden J, Hartog J. Serotonergic modulation of social interactions in isolated male mice. Psychopharmacology (Berl.), 97, 154-156 (1989).
95. White SM, Kucharik RF, Moyer JA. Effects of serotonergic agents on isolation-induced aggression. Pharmacol. Biochem. Behav., 39, 729-736 (1991).
96. Sánchez C, Arnt J, Hyttel J, Moltzen EK. The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology (Berl.), 110, 53-59 (1993).
97. De Boer SF, Lesourd M, Mocaer E, Koolhaas JM. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: a comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J. Pharmacol. Exp. Ther., 288, 1125-1133 (1999).
98. Mendoza DL, Bravo HA, Swanson HH. Antiaggressive and anxiolytic effects of gepirone in mice, and their attenuation by WAY 100635. Pharmacol. Biochem. Behav., 62, 499-509 (1999).
99. van Erp AM, Miczek KA. Aggressive behavior, increased accumbal dopamine, and decreased cortical serotonin in rats. J. Neurosci., 20, 9320-9325 (2000).
100. Anstrom KK, Miczek KA, Budygin EA. Increased phasic dopamine signaling in the mesolimbic pathway during social defeat in rats. Neuroscience, 161, 3-12 (2009).
101. Ago Y, Araki R, Tanaka T, Sasaga A, Nishiyama S, Takuma K, Matsuda T. Role of social encounter-induced activation of prefrontal serotonergic systems in the abnormal behaviors of isolationreared mice. Neuropsychopharmacology, 38, 1535-1547 (2013).
102. Ago Y, Araki R, Yano K, Kawasaki T, Chaki S, Nakazato A, Onoe H, Hashimoto H, Baba A, Takuma K, Matsuda T. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice. J. Pharmacol. Sci., 118, 295-298 (2012).
103. Berrocoso E, Mico JA. Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice. Int. J. Neuropsychopharmacol., 12, 61-71 (2009).
104. Berrocoso E, De Benito MD, Mico JA. Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. Psychopharmacology (Berl.), 193, 97-105 (2007).
105. Colpaert FC, Tarayre JP, Koek W, Pauwels PJ, Bardin L, Xu XJ, Wiesenfeld-Hallin Z, Cosi C, Carilla-Durand E, Assié MB, Vacher B. Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology, 43, 945-958 (2002).
106. Colpaert FC. 5-HT1A receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr. Opin. Investig. Drugs, 7, 40-47 (2006).
107. Coudereau JP, Monier C, Bourre JM, Frances H. Effect of isolation on pain threshold and on different effects of morphine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 21, 997-1018 (1997).
108. Horiguchi N, Ago Y, Asada K, Kita Y, Hiramatsu N, Takuma K, Matsuda T. Involvement of spinal 5-HT1A receptors in isolation rearing-induced hypoalgesia in mice. Psychopharmacology (Berl.), 227, 251-261 (2013).
109. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci., 23, 238-245 (2002).
110. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, Matsuda T. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacology, 55, 1355-1363 (2008).
111. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav. Brain Res., 156, 105-114 (2005).
112. Johnson SA, Fournier NM, Kalynchuk LE. Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav. Brain Res., 168, 280-288 (2006).
113. Kalynchuk LE, Gregus A, Boudreau D, Perrot-Sinal TS. Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav. Neurosci., 118, 1365-1377 (2004).
114. Zhao Y, Ma R, Shen J, Su H, Xing D, Du L. A mouse model of depression induced by repeated corticosterone injections. Eur. J. Pharmacol., 581, 113-120 (2008).
115. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol., 21, 516-521 (2001).
116. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry, 60, 1343-1349 (2006).
117. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology, 31, 628-636 (2006).
118. Butts KA, Phillips AG. Glucocorticoid receptors in the prefrontal cortex regulated dopamine efflux to stress via descending glutamataergic feedback to the ventral tegmental area. Int. J. Neuropsychopharmacol., 16, 1799-1807 (2013).
119. Czyrak A, Maćkowiak M, Chocyk A, Fijał K, Ga̧dek-Michalska A, Wȩdzony K. 8-OHDPAT-induced disruption of prepulse inhibition in rats is attenuated by prolonged corticosterone treatment. Neuropsychopharmacology, 28, 1300-1310 (2003).
120. Saphier D, Farrar GE, Welch JE. Differential inhibition of stressinduced adrenocortical responses by 5-HT1A agonists and by 5-HT2 and 5-HT3 antagonists. Psychoneuroendocrinology, 20, 239-257 (1995).
121. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology, 65, 29-38 (2013).
122. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, Matsuda T. Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity. Synapse, 63, 7-14 (2009).
123. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev., 25, 192-216 (1997).
124. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev., 11, 157-198 (1986).
125. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev., 16, 223-244 (1991).
126. Przegaliński E, Siwanowicz J, Baran L, Filip M. Activation of serotonin (5-HT)1A receptors inhibits amphetamine sensitization in mice. Life Sci., 66, 1011-1019 (2000).
127. Przegalinski E, Siwanowicz J, Nowak E, Papla I, Filip M. Role of 5-HT1B receptors in the sensitization to amphetamine in mice. Eur. J. Pharmacol., 422, 91-99 (2001).
128. Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, Matsuda T. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology, 51, 914-922 (2006).
129. Ago Y, Nakamura S, Kajita N, Uda M, Hashimoto H, Baba A, Matsuda T. Ritanserin reverses repeated methamphetamineinduced behavioral and neurochemical sensitization in mice. Synapse, 61, 757-763 (2007).
130. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol., 33, 639-677 (1993).
131. Ago Y, Nakamura S, Baba A, Matsuda T. Neuropsychotoxicity of abused drugs: Effects of serotonin receptor ligands on methamphetamine-and cocaine-induced behavioral sensitization in mice. J. Pharmacol. Sci., 106, 15-21 (2008).
132. Ago Y, Tanaka T, Kita Y, Tokumoto H, Takuma K, Matsuda T. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release. Neuropharmacology, 62, 1634-1639 (2012).
133. Ago Y, Nakamura S, Hayashi A, Itoh S, Baba A, Matsuda T. Effects of osemozotan, ritanserin and azasetron on cocaineinduced behavioral sensitization in mice. Pharmacol. Biochem. Behav., 85, 198-205 (2006).
134. Nakamura S, Ago Y, Hayashi A, Itoh S, Kakuda M, Hashimoto H, Baba A, Matsuda T. Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice. Synapse, 60, 479-484 (2006).
135. Ago Y, Araki R, Yano K, Hiramatsu N, Kawasaki T, Chaki S, Nakazato A, Onoe H, Hashimoto H, Baba A, Takuma K, Matsuda T. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology (Berl.), 217, 443-452 (2011).
136. Ago Y, Hiramatsu N, Ishihama T, Hazama K, Hayata-Takano A, Shibasaki Y, Shintani N, Hashimoto H, Kawasaki T, Onoe H, Chaki S, Nakazato A, Baba A, Takuma K, Matsuda T. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide. Behav. Pharmacol., 24, 74-77 (2013).
137. Ago Y, Nakamura S, Baba A, Matsuda T. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology, 30, 43-51 (2005).
138. Ago Y, Harasawa T, Itoh S, Nakamura S, Baba A, Matsuda T. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice. Eur. J. Pharmacol., 520, 86-90 (2005).
139. Ago Y, Sato M, Nakamura S, Baba A, Matsuda T. Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. J. Pharmacol. Sci., 102, 419-422 (2006).
140. Egashira N, Harada S, Okuno R, Matsushita M, Nishimura R, Mishima K, Iwasaki K, Orito K, Fujiwara M. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marbleburying behavior: comparison with paroxetine. Eur. J. Pharmacol., 563, 149-154 (2007).
141. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology, 32, 514-521 (2007).
142. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum. Psychopharmacol., 25, 193-200 (2010).
143. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE, 3, e2558 (2008).
144. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol. Psychiatry, 62, 878-883 (2007).
145. Bermack JE, Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci., 97, 317-336 (2005).
146. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. Pharmacology and therapeutic potential of sigma1 receptor ligands. Curr. Neuropharmacol., 6, 344-366 (2008).
147. Delgado PL. Depression: the case for a monoamine deficiency. J. Clin. Psychiatry, 61 (Suppl. , 7-11 (2000).
148. Delgado PL, Moreno FA. Role of norepinephrine in depression. J. Clin. Psychiatry, 61 (Suppl. , 5-12 (2000).
149. Kobayashi T, Matsuno K, Murai M, Mita S. ρ1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res., 22, 1105-1109 (1997).
150. Rhodes ME, Li PK, Flood JF, Johnson DA. Enhancement of hippocampal acetylcholine release by the neurosteroid dehydroepiandrosterone sulfate: an in vivo microdialysis study. Brain Res., 733, 284-286 (1996).
151. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. Prog. Neurobiol., 89, 134-152 (2009).
152. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl.), 160, 353-361 (2002).
153. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur. J. Pharmacol., 647, 90-96 (2010).
154. Phan VL, Su TP, Privat A, Maurice T. Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect ρ1 receptor-mediated behaviour in mice. Eur. J. Neurosci., 11, 2385-2396 (1999).
155. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by ρ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther., 298, 1269-1279 (2001).
156. Ago Y, Yano K, Hiramatsu N, Takuma K, Matsuda T. Fluvoxamine enhances
157. Hiramatsu N, Ago Y, Hasebe S, Nishimura A, Mori K, Takuma K, Matsuda T. Synergistic effect of 5-HT1A and ρ1 receptor activation on prefrontal dopaminergic transmission under circulating steroid deficiency. Neuropharmacology, 75, 53-61 (2013).